Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial.
BACKGROUND: Homocysteine is a risk factor for Alzheimer's disease. In the first report on the VITACOG trial, we showed that homocysteine-lowering treatment with B vitamins slows the rate of brain atrophy in mild cognitive impairment (MCI). Here we report the effect of B vitamins on cognitive a...
Príomhchruthaitheoirí: | de Jager, C, Oulhaj, A, Jacoby, R, Refsum, H, Smith, A |
---|---|
Formáid: | Journal article |
Teanga: | English |
Foilsithe / Cruthaithe: |
2012
|
Míreanna comhchosúla
Míreanna comhchosúla
-
Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: A randomized controlled trial
de réir: De Jager, C, et al.
Foilsithe / Cruthaithe: (2012) -
Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: A randomized controlled trial
de réir: De Jager, C, et al.
Foilsithe / Cruthaithe: (2012) -
Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial.
de réir: Smith, A, et al.
Foilsithe / Cruthaithe: (2010) -
Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial.
de réir: Smith, A, et al.
Foilsithe / Cruthaithe: (2010) -
Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial
de réir: Smith, A, et al.
Foilsithe / Cruthaithe: (2010)